GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » EV-to-EBIT

Biocon (NSE:BIOCON) EV-to-EBIT : 21.41 (As of Jun. 01, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Biocon EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biocon's Enterprise Value is ₹596,081 Mil. Biocon's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹27,840 Mil. Therefore, Biocon's EV-to-EBIT for today is 21.41.

The historical rank and industry rank for Biocon's EV-to-EBIT or its related term are showing as below:

NSE:BIOCON' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.19   Med: 27.64   Max: 60.6
Current: 21.41

During the past 13 years, the highest EV-to-EBIT of Biocon was 60.60. The lowest was 11.19. And the median was 27.64.

NSE:BIOCON's EV-to-EBIT is ranked worse than
68.72% of 470 companies
in the Biotechnology industry
Industry Median: 8.875 vs NSE:BIOCON: 21.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biocon's Enterprise Value for the quarter that ended in Mar. 2025 was ₹603,449 Mil. Biocon's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹27,840 Mil. Biocon's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 4.61%.


Biocon EV-to-EBIT Historical Data

The historical data trend for Biocon's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon EV-to-EBIT Chart

Biocon Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.01 41.97 33.09 20.11 21.65

Biocon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.11 12.13 18.90 16.63 21.65

Competitive Comparison of Biocon's EV-to-EBIT

For the Biotechnology subindustry, Biocon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biocon's EV-to-EBIT falls into.


;
;

Biocon EV-to-EBIT Calculation

Biocon's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=596081.066/27840
=21.41

Biocon's current Enterprise Value is ₹596,081 Mil.
Biocon's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27,840 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocon  (NSE:BIOCON) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biocon's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=27840/603449.1271
=4.61 %

Biocon's Enterprise Value for the quarter that ended in Mar. 2025 was ₹603,449 Mil.
Biocon's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27,840 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocon EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biocon's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocon Business Description

Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.

Biocon Headlines

No Headlines